KIT and gastrointestinal stromal tumor: Thought to differentiate into Cajal cells, the majority of gastrointestinal stromal tumors (GISTs) harbor mutually exclusive KIT or PDGFRA mutations, which drive tumorigenesis and dictate responses to imatinib [1,2,3].